Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist

药代动力学 医学 血液透析 加药 内科学 肾功能 尿 药效学 终末期肾病 耐火材料(行星科学) 泌尿科 肾脏疾病 敌手 胃肠病学 受体 物理 天体生物学
作者
Jesse C. Nussbaum,Azher Hussain,K. Chris Min,Thomas Marbury,Kenneth C. Lasseter,S. Aubrey Stoch,Marian Iwamoto
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
卷期号:62 (11): 1435-1444 被引量:4
标识
DOI:10.1002/jcph.2094
摘要

Abstract Gefapixant, a P2X3 receptor antagonist, has demonstrated efficacy in patients with refractory or unexplained chronic cough. We investigated the effect of renal impairment (RI) on the pharmacokinetics (PK) of gefapixant 50 mg in an open‐label, single‐dose study enrolling participants with moderate (n = 6) or severe (n = 6) RI, end‐stage renal disease (ESRD; n = 6) under hemodialysis (HD) and non‐HD conditions, and healthy matched controls (n = 6). Serial plasma and urine samples for gefapixant concentrations were collected at selected time points over 72 and 48 hours after dosing, respectively. Linear regression analysis predicted a 1.87‐, 2.79‐, and 3.76‐fold higher exposure (area under the plasma concentration–time curve) for participants with mild, moderate, and severe RI, respectively, than that for healthy matched control participants. Categorical analysis exhibited a 2.98‐, 4.43‐, and 4.74‐fold higher exposure for participants with moderate RI, severe RI, and ESRD, respectively, than that for healthy matched control participants. Apparent oral clearance and renal clearance was lower in participants with various degrees of RI, by 66% to 90%, compared with healthy matched control participants, explaining the increased gefapixant exposure with increasing degrees of renal impairment. Gefapixant area under the plasma concentration–time curve and maximum plasma concentration decreased by ≈25% under HD conditions compared to non‐HD conditions. Single‐dose administration of gefapixant was generally well tolerated in this study. The data from this trial informed the enrollment of phase 3 clinical trials that evaluated the efficacy and safety of gefapixant in >2000 participants with refractory or unexplained chronic cough. Those efficacy and safety data, combined with analysis of population pharmacokinetics from across the entire development program, will be used to evaluate the magnitude of the renal impairment effect in the refractory or unexplained chronic cough population and to determine any dose adjustment recommendations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
楠楠DAYTOY发布了新的文献求助10
刚刚
慕1完成签到,获得积分10
刚刚
zcyuqing发布了新的文献求助10
1秒前
1秒前
慢慢发布了新的文献求助10
1秒前
1秒前
整齐的幻翠完成签到 ,获得积分10
1秒前
Lucas的应助被624794951采纳,获得10
1秒前
1秒前
桃桃发布了新的文献求助10
2秒前
妮妮发布了新的文献求助10
2秒前
勤劳冥发布了新的文献求助10
3秒前
小狗发布了新的文献求助10
3秒前
小白发布了新的文献求助10
3秒前
3秒前
博nn发布了新的文献求助10
3秒前
arniu2008的应助被不知道叫什么采纳,获得20
3秒前
4秒前
完美世界的应助被欢呼的凤妖采纳,获得10
4秒前
哈哈哈的一笑完成签到,获得积分10
5秒前
5秒前
今后的应助被WangBobo采纳,获得10
5秒前
许愿发布了新的文献求助10
5秒前
清清清完成签到 ,获得积分10
5秒前
123发布了新的文献求助10
5秒前
6秒前
FashionBoy的应助被Nicolesix采纳,获得10
6秒前
李爱国的应助被jeak采纳,获得10
6秒前
6秒前
6秒前
7秒前
少双发布了新的文献求助10
7秒前
aaa发布了新的文献求助10
7秒前
7秒前
7秒前
lc完成签到,获得积分10
8秒前
酷波er的应助被孤独超短裙采纳,获得10
9秒前
9秒前
9秒前
完美世界的应助被GangBer采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162621
求助须知:如何正确求助?哪些是违规求助? 9556889
关于积分的说明 21737583
捐赠科研通 7753002
什么是DOI,文献DOI怎么找? 3427836
关于科研通互助平台的介绍 2552719
邀请新用户注册赠送积分活动 2472507